The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
It helps to cleanse our body from various toxins, fight diseases, and chronic illnesses very effectively
We will explore the following key areas: What Are GLP-1 Agonists
What Is Dry Eye
It's not a replacement for a balanced diet, good sleep, and regular care, but as a periodic wellness treatment, it's the classic, time-tested option, and a great entry point into IV therapy
Reverse Aging : Turn back the clock with powerful anti-aging properties